metformin has been researched along with Arrhythmias, Cardiac in 15 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Arrhythmias, Cardiac: Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the use of sulphonylurea monotherapy, compared with metformin monotherapy, is associated with an increased risk of ventricular arrhythmia (VA) among patients initiating pharmacotherapy for type 2 diabetes." | 8.31 | Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study. ( Douros, A; Filion, KB; Islam, N; Reynier, P; Yu, OHY, 2023) |
| "Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause mortality." | 6.66 | Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. ( Chattipakorn, N; Chattipakorn, SC; Nantsupawat, T; Wongcharoen, W, 2020) |
| " Moreover, compared to diabetic untreated and metformin-treated animals, those treated with PAP1 had the lowest risk of developing the life-threatening arrhythmia Torsade de Pointes under cardiac challenge." | 4.31 | Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats. ( Alquiza, A; Casis, O; Echeazarra, L; Fernández-López, V; Gallego, M; Rodríguez-de-Yurre, A; Zayas-Arrabal, J, 2023) |
| "To determine whether the use of sulphonylurea monotherapy, compared with metformin monotherapy, is associated with an increased risk of ventricular arrhythmia (VA) among patients initiating pharmacotherapy for type 2 diabetes." | 4.31 | Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study. ( Douros, A; Filion, KB; Islam, N; Reynier, P; Yu, OHY, 2023) |
| "Metformin treatment significantly reduced cardiac fibrosis and alleviated arrhythmia in the diabetic rats." | 3.88 | Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats. ( Cao, Q; Du, H; Duan, N; Fu, X; Li, B; Li, X; Pan, Y; Wang, S, 2018) |
| "Although both vildagliptin and metformin improved insulin resistance and attenuate myocardial injury caused by I/R, combined drugs provided better outcomes than single therapy by reducing arrhythmia score and mortality rate." | 3.80 | Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats. ( Apaijai, N; Chattipakorn, N; Chattipakorn, S; Chinda, K; Palee, S, 2014) |
| "After run-in on metformin and basal-bolus insulin (BBI), 102 participants continued metformin and basal insulin and were randomized to exenatide dosing before the two largest meals (glucacon-like peptide-1 receptor agonist and insulin [GLIPULIN group]) or continuation of rapid-acting insulin analogs (BBI group)." | 2.82 | Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. ( , 2016) |
| "Patients with type 2 diabetes are at increased susceptibility to a prolonged QT interval." | 2.79 | Lack of the QTc physiologic decrease during cardiac stress test in patients with type 2 diabetes treated with secretagogues. ( Amato, S; Baiocco, E; Curione, M; Di Bona, S; Gatti, A; Mandosi, E; Morano, S; Rossetti, M; Salvatore, S; Tarquini, G; Turinese, I; Varrenti, M, 2014) |
| "Glyburide was associated with a significant increase in QTc (433 +/- 24 to 467 +/- 24 ms, p <0." | 2.70 | Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K+ channel effect. ( Khan, IA; Molnar, J; Najeed, SA; Somberg, JC, 2002) |
| "Metformin has been shown to have various cardiovascular benefits beyond its antihyperglycemic effects, including a reduction in stroke, heart failure, myocardial infarction, cardiovascular death, and all-cause mortality." | 2.66 | Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient. ( Chattipakorn, N; Chattipakorn, SC; Nantsupawat, T; Wongcharoen, W, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 7 (46.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zayas-Arrabal, J | 2 |
| Alquiza, A | 1 |
| Rodríguez-de-Yurre, A | 1 |
| Echeazarra, L | 2 |
| Fernández-López, V | 1 |
| Gallego, M | 2 |
| Casis, O | 2 |
| Malagueta-Vieira, L | 1 |
| Fernández-Ruocco, J | 1 |
| Hortigón-Vinagre, MP | 1 |
| Zamora, V | 1 |
| Smith, GL | 1 |
| Vila Petroff, M | 1 |
| Medei, E | 1 |
| Lee, TTL | 1 |
| Hui, JMH | 1 |
| Lee, YHA | 1 |
| Satti, DI | 1 |
| Shum, YKL | 1 |
| Kiu, PTH | 1 |
| Wai, AKC | 1 |
| Liu, T | 1 |
| Wong, WT | 1 |
| Chan, JSK | 1 |
| Cheung, BMY | 1 |
| Wong, ICK | 1 |
| Cheng, SH | 1 |
| Tse, G | 1 |
| Islam, N | 1 |
| Reynier, P | 1 |
| Douros, A | 1 |
| Yu, OHY | 1 |
| Filion, KB | 1 |
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Villarroya, F | 1 |
| Palee, S | 2 |
| Higgins, L | 1 |
| Leech, T | 1 |
| Chattipakorn, SC | 2 |
| Chattipakorn, N | 3 |
| Nantsupawat, T | 1 |
| Wongcharoen, W | 1 |
| Fu, X | 1 |
| Pan, Y | 1 |
| Cao, Q | 1 |
| Li, B | 1 |
| Wang, S | 1 |
| Du, H | 1 |
| Duan, N | 1 |
| Li, X | 1 |
| Apaijai, N | 1 |
| Chinda, K | 1 |
| Chattipakorn, S | 1 |
| Urbinati, S | 1 |
| Bordoni, B | 1 |
| Curione, M | 1 |
| Di Bona, S | 1 |
| Amato, S | 1 |
| Turinese, I | 1 |
| Tarquini, G | 1 |
| Gatti, A | 1 |
| Mandosi, E | 1 |
| Rossetti, M | 1 |
| Varrenti, M | 1 |
| Salvatore, S | 1 |
| Baiocco, E | 1 |
| Morano, S | 1 |
| Najeed, SA | 1 |
| Khan, IA | 1 |
| Molnar, J | 1 |
| Somberg, JC | 1 |
| Davis, TM | 1 |
| Parsons, RW | 1 |
| Broadhurst, RJ | 1 |
| Hobbs, MS | 1 |
| Jamrozik, K | 1 |
| Yazar, A | 1 |
| Polat, G | 1 |
| Un, I | 1 |
| Levent, A | 1 |
| Kaygusuz, A | 1 |
| Büyükafşar, K | 1 |
| çamdeviren, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy And Safety Of Metformin For The Treatment Of Atrial Fibrillation[NCT05878535] | Phase 4 | 770 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | ||
| FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes[NCT05653518] | 40 participants (Anticipated) | Interventional | 2023-09-09 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
| Intervention | percentage (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -2.43 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | % of HbA1C (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 7.1 |
| Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | 0 |
| Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
| Intervention | kg (Mean) |
|---|---|
| Insulin Glargine, Metformin, Exenatide | -4.8 |
| Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
1 review available for metformin and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Effects of metformin on atrial and ventricular arrhythmias: evidence from cell to patient.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Atria; Heart Rate; H | 2020 |
4 trials available for metformin and Arrhythmias, Cardiac
10 other studies available for metformin and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Kv1.3 Channel Blockade Improves Inflammatory Profile, Reduces Cardiac Electrical Remodeling, and Prevents Arrhythmia in Type 2 Diabetic Rats.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Cytokines; Diabetes Mellitus, Experimental; Diabet | 2023 |
Metformin Reduces Potassium Currents and Prolongs Repolarization in Non-Diabetic Heart.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Diabetes Mellitus, Type 2; HEK293 Cells; Humans; I | 2022 |
Sulfonylurea Is Associated With Higher Risks of Ventricular Arrhythmia or Sudden Cardiac Death Compared With Metformin: A Population-Based Cohort Study.
Topics: Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cohort Studies; Death, Sudden, Cardiac; Diabetes Mell | 2022 |
Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
Topics: Arrhythmias, Cardiac; Cohort Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metfor | 2023 |
Acute metformin treatment provides cardioprotection via improved mitochondrial function in cardiac ischemia / reperfusion injury.
Topics: Animals; Apoptosis; Arrhythmias, Cardiac; Cardiotonic Agents; Heart Function Tests; Hypoglycemic Age | 2020 |
Metformin restores electrophysiology of small conductance calcium-activated potassium channels in the atrium of GK diabetic rats.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diabetes Mellitus; Disease | 2018 |
Combined vildagliptin and metformin exert better cardioprotection than monotherapy against ischemia-reperfusion injury in obese-insulin resistant rats.
Topics: Adamantane; Animals; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Dipeptidyl-Peptidase IV Inhi | 2014 |
[European guidelines on diabetes, pre-diabetes and cardiovascular diseases: what's new?].
Topics: Arrhythmias, Cardiac; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type | 2014 |
Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment.
Topics: Adult; Arrhythmias, Cardiac; Diabetes Complications; Diabetes Mellitus; Digitalis Glycosides; Diuret | 1998 |
Effects of glibenclamide, metformin and insulin on the incidence and latency of death by oubain-induced arrhythmias in mice.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Glucose; Cardiotonic Agents; Female; Gl | 2002 |